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Abstract: Chronic Hepatitis C infection is a global health problem. While primary infection 
is often inapparent, it becomes chronic in most cases. Chronic infection with Hepatitis C 
virus (HCV) frequently leads to liver cirrhosis or liver cancer. Consequently, HCV infection 
is one of the leading causes for liver transplantation in industrialized countries. Current 
treatment is not HCV specific and is only effective in about half of the infected patients. 
This situation underlines the need for new antivirals against HCV. To develop new and 
more efficient drugs, it is essential to specifically target the different steps of the viral life 
cycle. Of those steps, the targeting of HCV assembly has the potential to abolish virus 
production. This review summarizes the advances in our understanding of HCV particle 
assembly and the identification of new antiviral targets of potential interest in this late step 
of the HCV life cycle. 
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1. Introduction 
HCV  is  the  agent  that  causes  Hepatitis  C,  a  disease  that  affects  around  130  million  people 
worldwide. Primary infection with HCV often shows only mild symptoms, but in the majority of 
patients,  the  infection  becomes  chronic  and  leads  to  liver  cirrhosis,  which  often  results  in  liver 
cancer [1]. HCV infection is currently one of the major reasons for liver transplantation in Europe and 
in the United States. There is no vaccine available to protect against HCV and vaccine development is 
severely hampered by the weak immune response to HCV infection, by the wide variety of HCV 
genotypes, and by the lack of an immunocompetent small animal model for HCV. HCV infection is 
currently treated with pegylated interferon α and ribavirin, but treatment is only effective in about half 
of  the  infected  patients,  and  the  success  of  the  therapy  is  highly  dependent  on  the  genotype  of 
HCV [1].  Furthermore,  current  treatment,  which  is  mainly  immunostimulatory,  targets  cellular 
processes  rather  than  viral  proteins,  and  treatment  is  therefore  often  accompanied  by  several, 
sometimes  severe,  side  effects.  Obviously,  there  is  an  urgent  need  for  the  development  of  new 
antivirals  that  will  achieve  better  treatment  efficacy.  In  particular,  antiviral  drugs  that  target  viral 
proteins and viral specific processes, instead of broad host processes, are required.  
HCV is a small enveloped RNA virus belonging to the Flaviviridae family, more precisely to the 
genus Hepacivirus [2]. HCV has a genome of 9600 nucleotides, which encodes a single polyprotein 
that is co- and post-translationally cleaved to produce different viral proteins. The N-terminal part of 
the polyprotein contains the structural proteins, the core protein (C), and the envelope proteins (E1 and 
E2). The rest of the polyprotein contains the p7 polypeptide, followed by the non-structural proteins 
NS2, NS3, NS4A, NS4B, NS5A, and NS5B (see Figure 1). In addition, infected patients produce 
antibodies against an alternate reading frame protein starting from the core encoding region [3]. So far, 
no  function  has  been  attributed  to  this  protein  and  its  identification  remains  elusive.  The  viral 
polymerase NS5B is error-prone, leading to a wide variability amongst different HCV genomes. Based 
on those sequence differences, HCV can be grouped into seven genotypes [4].  
HCV infection of the hepatocyte begins with a complex interaction of the virion with a series of 
cellular entry factors (for a review see [5]). The viral particle is then internalized by clathrin-mediated 
endocytosis [6,7]. This is followed by the release of the viral RNA into the cytosol. The genome is 
then translated and processed to generate the viral proteins. The non-structural proteins assemble the 
replication  complex,  which  is  tightly  linked  to  endoplasmic  reticulum  (ER)-derived  
membranes [8-10]. With the progressive accumulation of new genomic RNA and structural proteins, 
progeny viral particles are formed in an intracellular compartment and they are released from the cell 
through the secretory pathway. The viral lifecycle can be divided in three major phases: (i) entry and 
uncoating of the virus, (ii) translation and replication of the viral genome, and (iii) assembly and egress 
of the new viral particles (Figure 1). All of these steps are possible targets for antiviral drugs, which 
could greatly enhance current therapies.  
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Figure 1. Schematic representation of the viral life cycle and viral proteins. HCV is closely 
associated  with  very  light  density  lipoprotein  (VLDL)  particles.  Entry  of  this 
lipoviroparticle needs at least four essential entry factors, Scavenger Receptor Class B 
Type I, CD81, Claudin, and Occludin. Receptor binding is followed by clathrin-mediated 
endocytosis.  Viral  RNA  is  released  into  the  cytosol  and  serves  as  a  template  for  the 
production of the viral proteins (see inset) and for the negative strand, which will serve to 
produce  new  viral  genomic  RNA  (in  close  proximity  with  ER-derived  membranes). 
Assembly  starts  with  core  and  NS5A  recruitment  to  lipid  droplets  (LD),  followed  by 
particle formation. The virion interacts with VLDL particles. Lipoviroparticles undergo 
maturation during the transport through the Golgi apparatus and become more lipidated.  
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2. HCV Assembly 
2.1. Viral components of the assembly machinery 
As  components  of  the  HCV  particle,  the  RNA  genome,  the  core  protein,  and  the  envelope 
glycoproteins are essential elements in the assembly process. Since non-structural proteins NS3 to 
NS5B  have  essential  roles  in  replication,  it  was  long  thought  that  these  proteins  were  solely 
responsible for catalyzing the accumulation of genomic RNA molecules that could subsequently be 
packaged  by  the  structural  proteins.  This  hypothesis  was  initially  supported  by  the  ability  of 
subgenomic  replicons  lacking  the  structural  region  to  efficiently  undergo  RNA  synthesis [11,12]. 
However,  whereas  replication  is  independent  of  the  structural  proteins,  the  packaging  of  HCV 
genomes into infectious particles seems to require more than just the physical components of the 
virion. Indeed components of the replication complex, as well as the non-structural proteins p7 and 
NS2,  are  involved  in  HCV  morphogenesis.  Interestingly,  this  dual  function  of  the  non-structural 
proteins is emerging as a general feature of the assembly process in the Flaviviridae family [13]. 
2.2. The viral particle factory 
For a long time, it has been known that the HCV core accumulates around lipid droplets (LDs), 
which are storage organelles for neutral lipids, such as triglycerides and cholesterol esters [14-16]. 
However,  it  is  only  recently  that  LDs  were  identified  as  a  central  element  of  the  viral  particle 
factory [17]. The cleavage between the core protein and E1 in the polyprotein is mediated by a signal 
peptidase. However, the core protein needs to be further cleaved by a signal peptide peptidase in order 
to interact with LDs. This process leads to the mature core protein [18-20]. Based on amino acid 
distribution and hydrophobicity plots, the mature form of the HCV core protein can be divided into 
two domains, D1 and D2 [21-23]. The D1 domain is rich in basic residues and is comprised of the  
N-terminal two-thirds of the core, whereas D2 encompasses the C-terminus and is more hydrophobic. 
The  basic  clusters  of  the  D1  domain  are  thought  to  enable  core-RNA  interaction [18,24,25]. 
Furthermore,  core-core  interaction  has  been  mapped  to  amino  acids  in  the  middle  of  the  core 
sequence [26], whereas the D2 domain contains two amphipathic helices and a hydrophobic loop that 
are  necessary  for  interaction  with  LDs [22,27].  Interaction  of  the  core  protein  with  LDs  is  now 
recognized as essential for infectious virus production [27,28]. However, an inverse correlation has 
been observed between the extent of core-LD association and virus production, suggesting that these 
interactions are dynamic and regulated during virus assembly [29]. Furthermore, core proteins may 
also contribute to HCV assembly by inducing the relocation of LDs to the periphery of the nucleus and 
of those in close contact with the replication complex and the ER membranes [30].  
In addition to the core protein, some viral non-structural proteins like NS5A and NS3 are also found 
around  LDs  in  HCV  infected  cells [17].  However,  the  core-LD  association  is  essential  for  the 
recruitment of these other viral proteins and for virus production. The core protein has indeed been 
shown to recruit the non-structural proteins around the LDs by interacting with NS5A [31-33]. NS5A 
might therefore be the scaffold for the recruitment of the other non-structural proteins to the LDs. This 
process can explain how replication complexes, which contain the newly synthesized RNA genome 
and the non-structural proteins, are brought into contact with the core. Importantly, NS5A is emerging Viruses 2010, 2                                       
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as a protein that plays a double role in both the replication and the assembly processes. NS5A is a 
membrane-associated RNA-binding phosphoprotein composed of three domains and an N-terminal 
membrane  anchor [34-38].  Within  NS5A,  domain  I  has  been  proposed  to  be  involved  in  RNA 
replication, whereas domain III (DIII), which is dispensable for RNA replication, is a central player in 
HCV assembly [31-33]. It is increasingly clear that mutations that stabilize replication events tend to 
inhibit virion production. This indicates a close relationship between these processes [39-41]. A model 
has been proposed in which NS5A is maintained in the functional replicase via association with host 
factors,  but  dissociates  upon  phosphorylation,  leading  to  viral  particle  assembly [42,43].  In  fact, 
phosphorylation of NS5A at a cluster of serine residues in DIII is important for the interaction of 
NS5A with the core [44,45] and thus is critical for the start of the assembly process. 
Other proteins in the replication complex are also involved in HCV assembly. The identification of 
adaptive mutations in NS3 suggested a role for this protein in the assembly process  [46-48]. NS3 is a 
well characterized viral protein that has protease and helicase activities. NS3 cleaves the polyprotein 
between  the  different  non-structural  proteins,  starting  with  NS3,  and  is  thus  the  prime  target  for 
antiviral drugs that aim to abolish polyprotein processing.  
Current models propose that viral genomes are transported as part of the replication complexes to 
the core/NS5A-containing LDs, and that assembly takes place there. Replication occurs in dedicated 
ER-derived vesicles [8-10]. HCV infection induces clustering of LDs around the nucleus and in close 
contact with the ER, which might facilitate assembly by bringing replication complexes and core-
coated  LDs  into  close  contact.  Currently,  we  lack  information  regarding  core-RNA  association, 
formation of the nucleocapsid, and the mechanism by which core-RNA particles are packaged in the 
lipid envelope containing the envelope glycoproteins. Models propose that the interaction of core and 
genomic RNA via replication complexes at the LDs leads to the nucleocapsid formation with the help 
of NS5A close to the LDs. These particles then bud into the ER lumen, where they obtain their lipid 
envelope, which contains the viral glycoproteins.  
2.3. Involvement of p7 and NS2 in HCV assembly 
Besides the structural proteins and the viral components of the replication complex, the remaining 
HCV proteins, p7 and NS2, are also essential for HCV morphogenesis. Since NS2 is dispensable for 
HCV RNA replication, and it does not seem to be incorporated into viral particles [12], the protein has 
been suspected to be involved in the assembly process of the HCV particle. NS2 is a small membrane-
bound  protein  with  a  C-terminal  cytosolic  domain  that  is  bound  to  an N -terminal  transmembrane 
domain  that  might  contain  three  transmembrane  segments [49].  For  a  long  time,  the  only  known 
function of NS2 was its role in polyprotein processing as part of the auto-protease that cleaves in cis 
between  NS2  and  NS3.  However,  data  from  several  studies  that  have  used  the  HCV  cell  culture 
(HCVcc) system suggest the specific involvement of NS2 during the assembly of infectious HCV 
particles [49-53]. Indeed, compensatory mutations accumulating within the N-terminal domain of NS2 
following transfection of an inter-genotypic, 1a/2a chimeric viral RNA have been shown to enhance 
the specific infectivity of secreted virus particles [46]. Furthermore, the deletion of the NS2 sequence 
was shown to block infectious virus production by an otherwise viable bi-cistronic HCV RNA that no 
longer required the NS2-NS3 auto-protease for genome amplification [51]. Structural and functional Viruses 2010, 2                                       
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characterization
  of  the  NS2  transmembrane  domain  has  shown  that  this  domain  is
  essential  for 
infectious virus production [49]. In addition, the NS2 protease
 domain, but not its catalytic activity, is 
also essential for infectious virus assembly [49,51]. A reverse genetic analysis of NS2 in the HCVcc 
system  also  indicated  that  the  NS2  protein  contributes  to  virus  particle  assembly  via  opposing 
interactions with the E1E2 glycoprotein and the NS3-NS4A enzyme complexes [48]. Finally, it has 
been  proposed  that  NS2  is  involved  in  a  late  post-assembly  maturation  step [53].  Although  these 
studies strongly support a role for NS2 during virus assembly via a complex network of interactions 
involving other viral structural and non-structural proteins, the details of that role and how NS2 might 
act during the production of infectious virus particles remain unknown. 
Another viral protein involved in a late step of the HCV life cycle is the p7 polypeptide. HCV p7 is 
comprised  of  two  helical  domains  connected  by  a  polar  loop [54].  The  proteins  assemble  as  a 
hexamer [55]. HCV p7 is dispensable for genomic replication and there is no clear evidence of its 
incorporation into the viral particle. p7 has been shown to form cation-selective channels
 in artificial 
membranes [56-58], a property that likely
 depends on the oligomerization of the protein [55,59,60]. A 
detailed structure of an HCV p7 ion channel has recently been obtained by electron microscopy [55]. 
The density map at a resolution of around 16 Å reveals a flower-shaped protein architecture with 
protruding  petals  oriented  toward  the  ER  lumen.  This  broadest  part  of  the  channel  presents  a 
comparatively  large  surface  area,  which  can  provide  interaction  sites  for  cellular  proteins,  viral 
proteins, or both. Mutation analyses of p7 in the HCVcc system revealed a role for this polypeptide in 
virus  assembly  and  release [51,52,61].  However,  as  with  NS2,  the  precise  role  of  p7  in  HCV 
morphogenesis remains undetermined. 
2.4. HCV envelope glycoproteins and virion assembly 
HCV envelope glycoproteins, E1 and E2, are major components of the viral particle. These proteins 
are  sufficient  to  confer  infectivity  to  HCV  pseudotyped  retroviral  particles [62,63],  and  they  are 
essential  for  HCV  infectivity  in  cell  culture [64].  Each  protein  consists  of  a  large  N-terminal 
ectodomain and a C-terminal transmembrane domain that anchors each glycoprotein in a lipid bilayer. 
Both  ectodomains  are  heavily  glycosylated [65]  and  their  structure  is  stabilized  by  disulfide 
bridges [66]. Both transmembrane domains contain ER retention signals [67,68] that are responsible 
for their subcellular localization [69]. From the start, the fates of E1 and E2 glycoproteins are closely 
linked, as both proteins are expressed consecutively in the viral polyprotein [70]. Characterization of 
these  glycoproteins  using  heterologous  expression  systems  suggested  that  the  E1E2  non-covalent 
heterodimer is the functional complex for HCV entry [71,72]. However, in the context of the HCVcc 
system, virion-associated E1 and E2 envelope glycoproteins form large covalent complexes stabilized 
by  disulfide  bridges,  whereas  the  intracellular  forms  of  these  proteins  assemble  as  non-covalent 
heterodimers [73]. The presence of disulfide bridges between HCV envelope glycoproteins suggests 
that lateral protein-protein interactions, assisted by disulfide-bond formation, might play an active role 
in the budding process of the HCV particle. Interestingly, the functional subviral HCV particles can be 
produced  only  when  the  HCV  envelope  glycoproteins  are  expressed  in  lipoprotein-producing  cell 
lines [74,75], supporting the idea that the HCV envelope glycoproteins play an active role during the 
budding process.  Viruses 2010, 2                                       
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2.5. Very low density lipoproteins (VLDL) and HCV assembly 
The secreted viral particles that are found in cell culture supernatant or in the blood of infected 
patients are rich in triglycerides and contain apolipoprotein B (ApoB) and apolipoprotein E (ApoE), in 
addition to the viral structural components [76,77]. These particles are called lipoviroparticles and are 
the product of a close association between VLDL assembly and HCV assembly. Importantly, HCV 
infectivity correlates with the extent of the viral particle lipidation. Indeed, particles recovered from 
animals infected with HCVcc virus present lower density and increased specific infectivity compared 
to the original inoculum [78]. 
Lipoproteins are the form in which hydrophobic lipids can be transported in the bloodstream. VLDL 
are produced in the liver to export cholesterol and triglycerides. VLDL production starts with the 
expression  of  ApoB100,  a  highly  hydrophobic  protein,  which  is  lipidated  by  the  microsomal 
triglyceride  transfer  protein  (MTP),  leading  to  the  formation  of  a  poorly  lipidated  initial  form  of 
VLDL. These pre-VLDL are thought to fuse with luminal triglyceride droplets in an ApoE dependent 
manner, before being secreted from liver cells  [79].  
ApoB, ApoE, and MTP have been found in close association with replication complexes [77,80]. 
Their importance for HCV assembly has been verified by siRNA experiments and inhibitor studies. 
Several initial reports showed that the inhibition of both ApoB secretion and MTP activity inhibit HCV 
secretion [80-82], whereas later reports showed a direct correlation between ApoE and HCV secretion 
and direct interaction of NS5A and ApoE without any effect of ApoB on viral production [83,84]. 
ApoB and ApoE secretion in VLDL assembly are linked processes and influence each other, which 
might explain the initially detected effect of ApoB silencing (especially as ApoB is involved in the 
initial assembly of VLDL, and ApoE intervenes at a later step). Furthermore, the differences might in 
part be due to the use of slightly different viruses, as the virus used to show the ApoB independence 
was a highly replicating cell culture adapted virus. Nevertheless, further investigations into the role of 
the proteins in HCV assembly and release, as well as into VLDL assembly, are necessary to elucidate 
the exact mechanisms for these processes.  
2.6. Viral particle transport and release 
After  budding,  HCV  particles  are  transported  through  the  cellular  secretory  pathway  to  the 
extracellular milieu. The secretion and maturation of the virions have been well described for the 
flaviviruses [85]. However, the maturation of HCV particles seems to be fundamentally different from 
that  of  flaviviruses.  Intracellular  infectious  virus  can  be  detected  in  HCV-infected  cells [86], 
suggesting that these virions mature immediately, or rapidly, after their formation. Furthermore, in 
contrast to flaviviruses, post-assembly cleavage events in one of the envelope proteins do not seem to 
be  involved  in  HCV  maturation.  Finally,  despite  undergoing  low-pH-dependent  entry [6],  HCV 
particles are acid resistant, which indicates that unknown factor(s) during uptake, rather than during 
egress, prime the envelope proteins for fusion [87]. Importantly, even if HCV virions are infectious 
soon  after  they  are  formed,  they  undergo  physical  modification  during  egress,  as  shown  by  their 
decrease in density as they pass through the secretory pathway [86]. Due to their association with Viruses 2010, 2                                       
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VLDL during the assembly process, it is believed that these changes in virion density are due to the 
extensive lipidation of the VLDL moiety in the secretory pathway.  
3. Drug targets 
Although the cloning of the HCV genome more than 20 years ago [88] allowed a rapid analysis of 
its genomic organization, as well as a biochemical characterization of its proteins [89], the lack of a 
cell culture system to efficiently amplify this virus has long been a major obstacle for the study of the 
HCV  life  cycle.  Early  research  into  the  viral  life  cycle  used  surrogate  systems,  e.g.,  the  related 
pestivirus bovine viral diarrhea virus (BVDV) [90]. However, several tools have been progressively 
developed  to  study  this  virus.  The  first  major  advance  in  the  field  was  the  development  of  a 
subgenomic replicon corresponding to a replicative mini-genome, which was the first tool available to 
study genomic replication [12]. This discovery was followed by the development of retroviral particles 
pseudotyped with the HCV envelope glycoproteins (HCVpp) to study HCV entry [63,91,92]. More 
recently, a cell culture system that allows for a relatively efficient amplification of HCV (HCVcc) has 
finally been developed [64,93,94]. This system is based on the transfection of the human hepatoma cell 
line Huh-7 with genomic HCV RNA, which was derived from a viral genome cloned from HCV. This 
HCV was isolated from a Japanese patient with fulminant hepatitis (JFH-1 isolate). Data accumulated 
with the HCVcc system sheds light on the life cycle of this virus. However, some limits still remain. 
So far, no other cell culture infectious virus has been isolated, and chimeric viruses seem to need the 
JFH-1 non-structural proteins to be infectious in cell culture. Additionally, only a limited number of 
cell  lines  are  susceptible  to  HCVcc  infection.  Furthermore,  there  are  distinct  differences  in  the 
lipidation and infectivity profile of infectious viruses derived from cell culture when compared to those 
derived  from  infected  patients/animals [78].  The  only  animal  naturally  susceptible  to  HCV  is  the 
chimpanzee, but a chimeric mouse model based on uPa/SCID mice colonized with human liver cells 
has been developed [95, 96]. Nevertheless, HCVcc allows for the successful analysis of all steps in the 
viral life cycle and has become a very useful tool in the screening of antiviral drugs.  
The current therapy against HCV results in a Sustained Virologic Response (SVR) for a fraction of 
the treated patients. This response is strongly dependent on the genotype of the virus. Thus, the SVR 
for  genotype  1,  which  is  the  most  frequent  genotype  in  the  Western  world,  is  around  50% [1]. 
Specifically  targeted  therapy  against  Hepatitis  C  (STAT-C)  targets  multiple  steps  and  is  quite 
advanced  in  the  drug  pipeline.  This  multiple  targeting  strategy  is  similar  to  the  Highly  Active 
Antiretroviral Therapy strategy (HAART) that is used for treating the human immunodeficiency virus 
(HIV). Drug development closely mirrors the development of HCV research tools. The biochemical 
and structural characterization of the NS3/4A protease and the NS5B polymerase, in the context of the 
replicon system, led to the development of several promising new antiviral molecules that block HCV 
replication [97], and which are most advanced in clinical studies. The accumulation of knowledge 
helped by the use of the HCVpp system is also leading to the preclinical development of molecules 
blocking viral entry [98]. Research into assembly and release only became possible with the first cell 
culture infectious virus in 2005 [64,93,94], and is therefore lagging. Nevertheless, interfering with 
HCV assembly also holds promise for drug design and discovery. The possibility of interference is Viruses 2010, 2                                       
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becoming  more  accessible  as  the  understanding  of  the  molecular  mechanisms  underlying  HCV 
morphogenesis advances. 
Although several protease and polymerase inhibitors are currently in advanced clinical studies [99], 
the need for additional anti-HCV drugs remains. The emergence of strains resistant to these new drugs 
is fast. Therefore, it is important to increase the pool of potential antivirals directed against HCV.  
Drugs targeting viral assembly can have several advantages. The prevention of assembly might lead 
to a rapid drop in viral titers in the blood of infected patients after the start of the treatment because 
components that were already produced can no longer be packaged into infectious particles. This, like 
other  antivirals,  will  limit  viral  spreading,  but  can  work  more  quickly  than  replication  inhibitors. 
Furthermore, infected cells treated with assembly inhibitors might induce a stronger antibody based 
immune response than those of untreated cells. This is because an excess of accumulated and then 
degraded viral protein in the cell leads to higher antigen presentation. Similarly, the innate immune 
response, which is curiously weak in HCV, might be activated due to an excess of viral RNA in 
infected  cells.  This,  however,  can  be  counteracted  by  viral  proteins  that  inhibit  the  Interferon  β 
response (e.g., the cleavage of MAVS by NS3/4A [100]). However, the intracellular accumulation of 
viral  genomes  and  proteins  might  also  prove  to  be  a  problem  for  assembly  inhibitors,  as  high 
concentration might favor unorthodox assembly and escape.  
More important than the advantages or disadvantages of single therapy is the consideration of a 
combined therapy that targets different steps of the viral life cycle. This can limit the emergence of 
resistance mutation, as selection pressure is applied not to a single viral function, but to several vital 
processes. For example, in combination therapy, even genomes that replicate in spite of polymerase 
inhibitors would not be packaged without the accumulation of further mutations to overcome assembly 
inhibition. Combined with the current treatment, which is mostly immunostimulatory, this might even 
lead  to  the  complete  elimination  of  the  virus.  Combination  therapy  with  three  different  drugs  is 
currently the standard for treatment against HIV (WHO guidelines). HIV is another virus for which the 
assembly s t e p   is  slowly  emerging  as  a  possible  target  for  drugs.  Indeed,  several  betulinic  acid 
derivatives, which inhibit virion formation by inhibiting gag cleavage, made it into clinical trials [101]. 
However, for most pathogens, the development of assembly inhibiting drugs is generally lagging. 
The assembly process contains several attractive targets for drug development. This ranges from the 
obvious viral proteins, which are essential for viral assembly and release, to the cellular factors that are 
important for these processes. The major proteins of assembly and the drugs directed against them are 
outlined in the following section. 
3.1. Possible viral targets and existing drugs 
Core. The association of core protein with lipid droplets and core-RNA multimerization is among 
the first steps in viral assembly (Figure 2: 4 and 6). The core can oligomerize, and truncated versions 
have  been  shown  to  self-assemble [102],  with  the  core-core  interaction  being  mapped  to  the  
N-terminal  part  of  the  protein.  Core  oligomerization  and  interaction  with  HCV  genomic  RNA  is 
thought to be an early step of virus assembly. Viral genomes containing mutations that abolish core 
dimerization are unable to produce infectious viruses in spite of normal replication rates [47]. A recent 
screen of two different compound libraries identified several hits of compounds that were able to Viruses 2010, 2                                       
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abolish  core  dimerization  in vitro [103].  Nevertheless,  before  these  results  can  translate  into  real 
antiviral drugs, extensive further testing is first necessary to gauge their toxicity in cell culture and 
animals, and their effect on HCVcc infection.  
Figure  2.  Schematic  representation  of  the  assembly  and  release  of  HCV.  Replication 
occurs at dedicated ER-derived membranes. Core and NS5A interact with lipid droplets 
and recruit the other non-structural proteins, and with them, the replication complex. Core 
and  genomic  RNA  interact  and  oligomerize,  and  must  interact  with  the  envelope 
glycoproteins to form the viral particle. The viral particle interacts with the VLDL. VLDL 
assembly  is  depicted  on  the  left  side.  ApoB  interacts  with  triglycerides  in  an M T P -
dependent manner to form a pre-VLDL, which will accumulate more lipids and ApoE in 
an MTP dependent process. Both the VLDL and the virus continue to undergo maturation 
during their passage through the secretory pathway. Red blocks mark potential drug targets 
in  this  process:  (1)  inhibition  of  the  interaction  of  NS5A  with  LD  or  the  other  non-
structural proteins, thus blocking their recruitment to LDs; (2) inhibition of NS2, a late 
stage block of assembly; (3) inhibition of p7 (BIT225 for example); (4) inhibition of the 
interaction of the core with LDs; (5) inhibition of the maturation of envelope proteins 
(inhibitors of α-glycosidases); (6) inhibition of core oligomerization and interaction with 
RNA;  (7)  inhibition  of  virus-VLDL  association;  (8)  inhibition  of  VLDL  secretion;  
(9)  inhibition  of  VLDL  formation  from  pre-VLDL  targeting  ApoE  and  MTP;  
(10)  inhibition  of  the f o rmation  of  pre-VLDL  by  the  MTP  dependent  association  of 
triglycerides with ApoB. 
 Viruses 2010, 2                                       
 
 
1792 
p7. p7 is the smallest protein encoded by the viral genome and forms an ion-channel [56-58]. For a 
long time, the protein was only considered to be a non-structural protein. p7 is essential for an early 
step  of  assembly  before  the  accumulation  of  intracellular  infectious  particles.  The  loss  of  p7 
completely abolishes the production of infectious particles, and the loss of channel activity interferes 
with virus production in cell culture [51,56,61] (Figure 2: 3). However, a recent report suggests the 
additional presence of p7 in the virion, due to the fact that cation-channel inhibitors can reduce viral 
entry, as well as inhibit assembly. However, this effect seems rather genotype dependent [104]. One of 
the  first  drugs  directed  against  p7  could  be  BIT225  (N-[5-(1-Methyl-1H-pyrazol-4-yl)-napthalene-
2carbonyl]-guanidine), which has clearly been shown to inhibit both p7 of HCV and the related p7 of 
BVDV. BIT225 has antiviral activity against BVDV and has gone through different phase I clinical 
trials, in which it induced a modest drop in the viral titers of treated patients [105]. Moreover, it was 
shown that N-nonyl deoxygalactonojirimycin (NN-DGJ), a galactose analog coupled to a long alkyl 
chain that does not inhibit α-glucosidases, interferes with p7 ion channel activity and inhibits the 
subsequent  release  of  infectious  particles  from  transfected  Huh-7  cells [57,106,107].  Finally,  the 
structural data recently obtained on p7 might enable the design of new, more specific cation-channel 
blockers, thus making p7 a very attractive drug target [55].  
NS3 and NS5A. NS3 combines protease and helicase activities [108,109]. The helicase domain of 
the protein has been shown to be essential for assembly [41]. Due to the fact that NS3 was one of the 
earliest  drug  targets  in  the  STAT-C  arsenal,  several  helicase  inhibitors  are  currently  under 
development. These molecules all inhibit replication and therefore do not present separate assembly 
inhibitors.  NS5A  was  shown  to  play  a  crucial  role  in  viral  assembly  in  addition  to  its  role  in 
replication. For the moment, there is no report of a compound that targets the function of NS5A in 
viral assembly. A replicon based screening identified a potent NS5A inhibitor (BMS-790052) for viral 
replication [110]. Screening in the HCVcc system might identify molecules that target both NS3 and 
NS5A for viral assembly, but not replication, as presented in the next subsection.  
NS2. NS2 is essential for a late stage in HCV assembly [49,51,53]. The protein might provide the 
link  between  early  core-RNA  complexes  and  the  ER-membrane  that  contains  the  envelope 
glycoproteins (Figure 2: 2). Unfortunately, the protease activity is not necessary for the functions of 
NS2  in  assembly [49,51],  thus  hindering  the  development  of  specific  drugs  until  the  exact 
requirements in NS2 for assembly have been characterized.  
Envelope glycoproteins. The envelope proteins E1 and E2 are highly glycosylated proteins. They 
are incorporated into the virion in a late assembly step. Their correct folding and conformation are 
important for the entry of HCV, both when they interact with the different receptors, and during the 
fusion process (Figure 2: 5). Both viral and endogenous glycoproteins use the same cellular folding 
machinery to reach their native conformation. Targeting the process of glycoprotein folding represents 
a novel antiviral strategy. The risk of emergence of viral escape mutants would be minimal since the 
targets are cellular enzymes – ER α-glucosidases. ER α-glucosidases I and II process glycans that 
enable the nascent glycoproteins to interact with ER lectin chaperones calnexin and calreticulin, which 
guide the glycoprotein towards its native conformation [111,112]. Iminosugars represent a class of 
glucose analogs that were shown to be potent inhibitors of ER α-glucosidases and to have antiviral 
activity  against  various  enveloped  viruses  by  their  interference  with  the  folding/oligomerization 
process of the envelope glycoproteins [107,113-115]. In vitro experiments have shown an antiviral Viruses 2010, 2                                       
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effect of different long alkyl chain imino sugar derivates [57,106,116]. Some compounds inhibit both 
p7  (by  blocking  the  cation-channel  activity)  and  the  ER  α-glucosidases,  and  probably  work  by  a 
combined  effect  of  the  p7  block  and  their  effect  on  E1  and  E2.  This  occurs  through  the  double 
impairment  of  both  the  assembly  of  infectious  particles  and  the  entry  of  newly  generated  viral 
particles.  Two  α-glucosidase-inhibitors,  UT-231B  (an  imminosugar)  and  celgosivir  (MX-3253  – a  
castanospermine prodrug), made it to phase II clinical trials, initially with very encouraging effects, 
especially for celgosivir. However, both have since been stopped: the phase II clinical trials with  
UT-231B  were  stopped  due  to  low  efficacy   [117,118],  and  the  clincal  trials  for  celgosivir  were 
stopped more recently with no precise reason given (as stated in the Migenix financial report for the 
first and second quarter of 2010). 
3.2. Possible cellular targets 
ApoB,  ApoE,  and  MTP.  It  has  been  shown  that  HCV  assembly  is  closely  linked  to  VLDL 
assembly; the VLDL assembly pathway might therefore contain possible drug targets to inhibit HCV 
assembly. For instance, the grapefruit flavonoid narigenin has been shown to inhibit VLDL secretion 
both in vitro and in vivo. Additionally, narigenin can inhibit HCV secretion in cell culture. Narigenin 
inhibits  ApoB  secretion  by  inhibiting  MTP  and  two  enzymes  involved  in  lipid  metabolism [81]. 
Following this line of reasoning, anti-arteriosclerosis drugs might also be tested for their effect on 
HCV infection, as several of them aim to lower blood cholesterol levels by repressing cholesterol 
export  from  the  liver  through  VLDL  inhibition,  e.g.,  by  inhibiting  MTP.  Currently,  several  MTP 
inhibitors are in clinical trials for the treatment of hypercholesterolemia or hyperlipidemia [119,120]. 
Furthermore, HCV infection has tentatively been linked to higher risk for arteriosclerosis development 
in a Japanese cohort [121].  
Nevertheless,  further  research  into  the  exact  relation  between  the  HCV  life  cycle  and  lipid 
metabolism is necessary to evaluate potential drugs that target lipid metabolism players. Thus, it might 
be necessary to analyze the differences between HCV genotypes. Clinical data show increased lipid 
synthesis in infected liver cells and decreased VLDL secretion, as well as a higher risk for steatosis, in 
patients chronically infected with genotype 3, but not in patients infected with genotype 1 in [122]. 
This suggests that the simple inhibition of VLDL assembly might not be sufficient to successfully treat 
HCV infection of all genotypes, and might even exacerbate the risk of steatosis in patients infected 
with genotype 3.  
3.3. Approved drugs that might potentially inhibit HCV assembly 
The HCVcc system has allowed the optimization of drug screening assays, which might identify 
novel molecules acting at different steps in the viral lifecycle  [123,124]. A recent screen of approved 
drugs by Gastaminza et al. [123] revealed the anti-assembly efficacy of two (potential) drugs from the 
National Institutes of Health clinical collection: pterostilbene and torimefene. Both pterostilbene and 
toremifene blocked viral spread in persistently infected cell cultures, but did not significantly influence 
entry or replication. The ratio between intracellular and extracellular infectivity indicates that the two 
drugs  might  act  downstream  of  replication, i nhibiting  assembly  or  release.  Pterostilbene  is  a 
component of blueberries corresponding to a methylated form of resveratrol and has been described to Viruses 2010, 2                                       
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have  antioxidative  effects.  Toremifene  is  a  derivative  of  tamoxifene.  Both  are  anti-cancer  drugs. 
Unfortunately, as a side effect, toremifene can induce hepatitis in cancer patients, indicating a certain 
liver toxicity for this substance, which makes it unsuitable as an anti-HCV drug. Nevertheless, these 
drugs  can  serve  as  a  basis  for  further  development  of  novel  drugs.  In  a  second  screen,  
Chockalingam  et.  al.  reported  that  quinidine  affected  viral  production  by  450-fold  relative  to 
replication [124], indicating a block of assembly/release. These new drug screening assays have the 
potential to identify new assembly inhibitors, which either could be developed further or could shed 
light on the assembly process itself.  
4. Conclusions 
Even though the development of HCV specific drugs is currently an ever increasing field, these 
drugs are mainly directed against the targets that have already been under investigation for a long time 
in the replicon or HCVpp systems. Research into assembly only became possible with the development 
of the HCVcc system and many aspects still remain unknown. However, viral assembly presents an 
attractive drug target and could ensure, in combination with the current immune stimulatory treatment 
and  protease  or  polymerase  inhibitors,  a  complete  clearance  of  the  virus,  or  at  least  a  significant 
reduction  of  viral  titers.  Although  there  are  very  few  drugs  already  in  the  stages  of  clinical 
investigation, several targets have already begun to emerge. Among the viral proteins, p7 seems to be 
the most promising target. The increasing knowledge of the HCV-VLDL interaction has opened a new 
field of possible target proteins. Thus, the prevention of VLDL assembly or the inhibition of the 
proteins shown to play a role in HCV release might prove to be a very effective way of treating HCV. 
Targeting essential cellular proteins instead of viral proteins has the additional advantage of a slower 
emergence for resistance. This advantage is sometimes bought dearly by more severe side effects. 
Since the development of the HCV cell culture system our knowledge has steadily increased. Thus, 
in the decade to come, we might see the same rise in antivirals targeting assembly functions, as we are 
currently seeing in antivirals targeting replication and polyprotein processing.  
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